The Experts below are selected from a list of 20823 Experts worldwide ranked by ideXlab platform
Stephanie Ravault - One of the best experts on this subject based on the ideXlab platform.
-
persistence of immune response to an adjuvanted varicella zoster virus Subunit Vaccine for up to year nine in older adults
Human Vaccines & Immunotherapeutics, 2018Co-Authors: Tino F Schwarz, Stephanie Volpe, Gregory Catteau, Roman Chlibek, Marie Pierre David, Jan Hendrik Richardus, Himal Lal, Lidia Oostvogels, Karlis Pauksens, Stephanie RavaultAbstract:Background: In adults aged ≥60 years, two doses of the herpes zoster Subunit Vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01B Adjuvant System) elicited humoral and cell-me...
A. Preusche - One of the best experts on this subject based on the ideXlab platform.
-
Open, Randomized Study to Compare the Immunogenicity and Reactogenicity of an Influenza Split Vaccine with an MF59-Adjuvanted Subunit Vaccine and a Virosome-Based Subunit Vaccine in Elderly
Infection, 2004Co-Authors: B. R. Ruf, K. Colberg, M. Frick, A. PreuscheAbstract:Background: An open, randomized, multicenter study was carried out in elderly to compare the immunogenicity and reactogenicity of a conventional influenza split Vaccine (SpV) with an MF59-adjuvanted Subunit Vaccine (aSuV) and a virosome-based Subunit Vaccine (vSuV) since earlier studies reported better immunogenicity for adjuvanted and virosome-based Vaccines. Patients and Methods: A total of 840 subjects, aged 60 years or more, who had not been vaccinated or diagnosed with influenza in the preceding season were investigated. Hemagglutination-inhibition antibody titers were measured, and signs and symptoms recorded. Results: The three Vaccines exceeded EU efficacy requirements for subjects aged older than 60 years and seroprotective levels (titers > 1:40) were equally maintained with the three Vaccines during 8 months post vaccination. SpV was as immunogenic as aSuV for the A/H3N2 strain (p < 0.0001) and significantly more immunogenic than aSuV for A/H1N1 strain (p = 0.0006). SpV was as immunogenic as vSuV for all three strains and significantly more immunogenic than vSuV for the A/H1N1 strain (p < 0.0001). In terms of reactogenicity, aSuV showed a higher rate of solicited local signs and symptoms than SpV (p = 0.021) and vSuV (p = 0.046), respectively. Incidence of solicited general symptoms was comparable on all treatments. No serious adverse event related to vaccination was reported. Conclusion: These findings suggest that all three Vaccines are highly immunogenic with an acceptable reactogenicity profile and that they are appropriate for use in elderly.
-
open randomized study to compare the immunogenicity and reactogenicity of an influenza split Vaccine with an mf59 adjuvanted Subunit Vaccine and a virosome based Subunit Vaccine in elderly
Infection, 2004Co-Authors: B. R. Ruf, K. Colberg, M. Frick, A. PreuscheAbstract:An open, randomized, multicenter study was carried out in elderly to compare the immunogenicity and reactogenicity of a conventional influenza split Vaccine (SpV) with an MF59-adjuvanted Subunit Vaccine (aSuV) and a virosome-based Subunit Vaccine (vSuV) since earlier studies reported better immunogenicity for adjuvanted and virosome-based Vaccines. A total of 840 subjects, aged 60 years or more, who had not been vaccinated or diagnosed with influenza in the preceding season were investigated. Hemagglutination-inhibition antibody titers were measured, and signs and symptoms recorded. The three Vaccines exceeded EU efficacy requirements for subjects aged older than 60 years and seroprotective levels (titers > 1:40) were equally maintained with the three Vaccines during 8 months post vaccination. SpV was as immunogenic as aSuV for the A/H3N2 strain (p < 0.0001) and significantly more immunogenic than aSuV for A/H1N1 strain (p = 0.0006). SpV was as immunogenic as vSuV for all three strains and significantly more immunogenic than vSuV for the A/H1N1 strain (p < 0.0001). In terms of reactogenicity, aSuV showed a higher rate of solicited local signs and symptoms than SpV (p = 0.021) and vSuV (p = 0.046), respectively. Incidence of solicited general symptoms was comparable on all treatments. No serious adverse event related to vaccination was reported. These findings suggest that all three Vaccines are highly immunogenic with an acceptable reactogenicity profile and that they are appropriate for use in elderly.
Gao-xue Wang - One of the best experts on this subject based on the ideXlab platform.
-
single walled carbon nanotubes as candidate recombinant Subunit Vaccine carrier for immunization of grass carp against grass carp reovirus
Fish & Shellfish Immunology, 2014Co-Authors: Bin Zhu, Guang-lu Liu, Yu-xin Gong, Fei Ling, Linsheng Song, Gao-xue WangAbstract:Grass carp reovirus (GCRV), the most pathogenic aquareovirus, can cause fatal hemorrhagic disease in fingerling and yearling grass carp. Vaccination by injection is by far the most effective method of combating disease. However it is labor intensive, costly and not feasible to vaccinate large numbers of the fish. Thus, an efficient and economic strategy for the prevention of GCRV infection becomes urgent. Here, functionalized single-walled carbon nanotubes (SWCNTs) as carrier were used to manufacture SWCNTs-VP7 Subunit Vaccine with chemical modification. Different developmental stages of grass carps were immunized by VP7/SWCNTs-VP7 Subunit Vaccine against GCRV by intramuscular injection and bath immunization. The results indicate that better immune responses of grass carp immunized with the SWCNTs-VP7 Subunit Vaccine were induced in comparison with VP7 Subunit Vaccine alone. Immunization doses/concentrations are significantly reduced (about 5-8 times) to prevent GCRV infection in different developmental stages of grass carp with injection or bath treatment when SWCNTs carrier was used. A good immune protective effect (relative percentage survival greater than 95%) is observed in smaller size fish (0.2 g) with SWCNT5-VP7 bath immunization. In addition, serum respiratory burst activity, complement activity, lysozyme activity, superoxide dismutase activity, alkaline phosphatase activity, immune-related genes and antibody levels were significantly enhanced in fish immunized with Vaccine. This study suggested that functionalized SWCNTs was the promising carrier for recombinant Subunit Vaccine and might be used to vaccinate fish by bath approach. (C) 2014 Elsevier Ltd. All rights reserved.
-
Single-walled carbon nanotubes as candidate recombinant Subunit Vaccine carrier for immunization of grass carp against grass carp reovirus
Fish & shellfish immunology, 2014Co-Authors: Bin Zhu, Guang-lu Liu, Yu-xin Gong, Fei Ling, Linsheng Song, Gao-xue WangAbstract:Grass carp reovirus (GCRV), the most pathogenic aquareovirus, can cause fatal hemorrhagic disease in fingerling and yearling grass carp. Vaccination by injection is by far the most effective method of combating disease. However it is labor intensive, costly and not feasible to vaccinate large numbers of the fish. Thus, an efficient and economic strategy for the prevention of GCRV infection becomes urgent. Here, functionalized single-walled carbon nanotubes (SWCNTs) as carrier were used to manufacture SWCNTs-VP7 Subunit Vaccine with chemical modification. Different developmental stages of grass carps were immunized by VP7/SWCNTs-VP7 Subunit Vaccine against GCRV by intramuscular injection and bath immunization. The results indicate that better immune responses of grass carp immunized with the SWCNTs-VP7 Subunit Vaccine were induced in comparison with VP7 Subunit Vaccine alone. Immunization doses/concentrations are significantly reduced (about 5-8 times) to prevent GCRV infection in different developmental stages of grass carp with injection or bath treatment when SWCNTs carrier was used. A good immune protective effect (relative percentage survival greater than 95%) is observed in smaller size fish (0.2 g) with SWCNTs-VP7 bath immunization. In addition, serum respiratory burst activity, complement activity, lysozyme activity, superoxide dismutase activity, alkaline phosphatase activity, immune-related genes and antibody levels were significantly enhanced in fish immunized with Vaccine. This study suggested that functionalized SWCNTs was the promising carrier for recombinant Subunit Vaccine and might be used to vaccinate fish by bath approach.
Bonto Faburay - One of the best experts on this subject based on the ideXlab platform.
-
A Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Confers Full Protection against Rift Valley Fever Challenge in Sheep
Scientific Reports, 2016Co-Authors: Bonto Faburay, William C. Wilson, Natasha N. Gaudreault, A. Sally Davis, Vinay Shivanna, Bhupinder Bawa, Sun Young Sunwoo, Barbara S. Drolet, Igor Morozov, D. Scott McveyAbstract:Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen causing disease outbreaks in Africa and the Arabian Peninsula. The virus has great potential for transboundary spread due to the presence of competent vectors in non-endemic areas. There is currently no fully licensed Vaccine suitable for use in livestock or humans outside endemic areas. Here we report the evaluation of the efficacy of a recombinant Subunit Vaccine based on the RVFV Gn and Gc glycoproteins. In a previous study, the Vaccine elicited strong virus neutralizing antibody responses in sheep and was DIVA ( d ifferentiating naturally i nfected from v accinated a nimals) compatible. In the current efficacy study, a group of sheep ( n = 5) was vaccinated subcutaneously with the glycoprotein-based Subunit Vaccine candidate and then subjected to heterologous challenge with the virulent Kenya-128B-15 RVFV strain. The Vaccine elicited high virus neutralizing antibody titers and conferred complete protection in all vaccinated sheep, as evidenced by prevention of viremia, fever and absence of RVFV-associated histopathological lesions. We conclude that the Subunit Vaccine platform represents a promising strategy for the prevention and control of RVFV infections in susceptible hosts.
-
a glycoprotein Subunit Vaccine elicits a strong rift valley fever virus neutralizing antibody response in sheep
Vector-borne and Zoonotic Diseases, 2014Co-Authors: Bonto Faburay, William C. Wilson, Igor Morozov, Maxim Lebedev, Scott D Mcvey, Alan Young, Juergen A RichtAbstract:Abstract Rift Valley fever virus (RVFV), a member of the Bunyaviridae family, is a mosquito-borne zoonotic pathogen that causes serious morbidity and mortality in livestock and humans. The recent spread of the virus beyond its traditional endemic boundaries in Africa to the Arabian Peninsula coupled with the presence of susceptible vectors in nonendemic countries has created increased interest in RVF Vaccines. Subunit Vaccines composed of specific virus proteins expressed in eukaryotic or prokaryotic expression systems are shown to elicit neutralizing antibodies in susceptible hosts. RVFV structural proteins, amino-terminus glycoprotein (Gn), and carboxyl-terminus glycoprotein (Gc), were expressed using a recombinant baculovirus expression system. The recombinant proteins were reconstituted as a GnGc Subunit Vaccine formulation and evaluated for immunogenicity in a target species, sheep. Six sheep were each immunized with a primary dose of 50 μg of each Vaccine immunogen with the adjuvant montanide ISA25;...
Roman Chlibek - One of the best experts on this subject based on the ideXlab platform.
-
persistence of immune response to an adjuvanted varicella zoster virus Subunit Vaccine for up to year nine in older adults
Human Vaccines & Immunotherapeutics, 2018Co-Authors: Tino F Schwarz, Stephanie Volpe, Gregory Catteau, Roman Chlibek, Marie Pierre David, Jan Hendrik Richardus, Himal Lal, Lidia Oostvogels, Karlis Pauksens, Stephanie RavaultAbstract:Background: In adults aged ≥60 years, two doses of the herpes zoster Subunit Vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01B Adjuvant System) elicited humoral and cell-me...
-
efficacy of the herpes zoster Subunit Vaccine in adults 70 years of age or older
The New England Journal of Medicine, 2016Co-Authors: Anthony L Cunningham, Roman Chlibek, Martina Kovac, Shinnjang Hwang, Javier Diezdomingo, Olivier Godeaux, Myron J Levin, Janet E Mcelhaney, Joan Puigbarbera, C Vanden AbeeleAbstract:BackgroundA trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster Subunit Vaccine (HZ/su) containing recombinant varicella–zoster virus glycoprotein E and the AS01B adjuvant system was associated with a risk of herpes zoster that was 97.2% lower than that associated with placebo. A second trial was performed concurrently at the same sites and examined the safety and efficacy of HZ/su in adults 70 years of age or older (ZOE-70). MethodsThis randomized, placebo-controlled, phase 3 trial was conducted in 18 countries and involved adults 70 years of age or older. Participants received two doses of HZ/su or placebo (assigned in a 1:1 ratio) administered intramuscularly 2 months apart. Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50. ResultsIn ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received either HZ/su (6950 participants) or placebo (69...
